SCHEMBL3517548

SCHEMBL3517548

O=c1c(-c2ccccc2)c(O)c2cc(F)cnc2n1O

nearest known ligand 0.44

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
KMT2A Q03164 2/20 0.44
LMNA P02545 2/20 0.42
SMN1; SMN2 Q16637 2/20 0.42
KDM4E B2RXH2 5/20 0.41
RCE1 Q9Y256 1/20 0.41
ALDH1A1 P00352 2/20 0.39
L3MBTL1 Q9Y468 2/20 0.39
TDP1 Q9NUW8 1/20 0.39
GAA P10253 1/20 0.39
PADI4 Q9UM07 3/20 0.37
MAPT P10636 2/20 0.36
CYP1A2 P05177 2/20 0.36
HSD17B10 Q99714 2/20 0.36
GRIN2D O15399 1/20 0.34
GRIN3B O60391 1/20 0.34
GRIN1 Q05586 1/20 0.34
GRIN2A Q12879 1/20 0.34
GRIN2B Q13224 1/20 0.34
GRIN2C Q14957 1/20 0.34
GRIN3A Q8TCU5 1/20 0.34

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL3525616 0.86 KMT2A (0.43) KMT2ALMNASMN1; SMN2KDM4ERCE1
SCHEMBL13435228 0.84 KDM4E (0.47) KMT2ALMNASMN1; SMN2KDM4ERCE1
SCHEMBL3518219 0.84 DPP4 (0.44) KMT2ALMNASMN1; SMN2KDM4ERCE1
SCHEMBL3515715 0.84 KMT2A (0.42) KMT2ALMNASMN1; SMN2KDM4ERCE1
SCHEMBL3516992 0.83 COMT (0.43) KMT2ALMNASMN1; SMN2KDM4ERCE1
SCHEMBL3517390 0.81 KDM4E (0.41) KMT2ALMNASMN1; SMN2KDM4ERCE1
SCHEMBL3519936 0.81 IP6K1 (0.41) KMT2ALMNASMN1; SMN2KDM4ERCE1
SCHEMBL3519938 0.81 IP6K1 (0.41) KMT2ALMNASMN1; SMN2KDM4ERCE1
SCHEMBL3518784 0.81 KMT2A (0.42) KMT2ALMNASMN1; SMN2KDM4ERCE1
SCHEMBL3518351 0.81 KDM4E (0.47) KMT2ALMNASMN1; SMN2KDM4ERCE1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20100056516-A1 1-HYDROXY NAPHTHYRIDINE COMPOUNDS AS ANTI-HIV AGENTS MERCK SHARP & DOHME CORP. 2010-03-04 US disclosed
US-20100056516-A1 1-HYDROXY NAPHTHYRIDINE COMPOUNDS AS ANTI-HIV AGENTS MERCK SHARP & DOHME CORP. 2010-03-04 US disclosed
US-20100056516-A1 1-HYDROXY NAPHTHYRIDINE COMPOUNDS AS ANTI-HIV AGENTS MERCK SHARP & DOHME CORP. 2010-03-04 US disclosed
WO-2008010964-A1 1-HYDROXY NAPHTHYRIDINE COMPOUNDS AS ANTI-HIV AGENTS MERCK & CO., INC. (US) 2008-01-24 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20100056516-A1 1-HYDROXY NAPHTHYRIDINE COMPOUNDS AS ANTI-HIV AGENTS RNASEH1, RNASE1, RNASEL KMT2A 2764/4885LMNA 658/4885SMN1; SMN2 1566/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.